Barely Significant
← all excerpts

Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.

J Ocul Pharmacol Ther · 2023 · PMC10654643 · PMID 37677000

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

nominally significantP < 0.05actually significant
In patients with moderate or severe DED ( n = 53), PL9643 treatment demonstrated either nominally significant ( P < 0.05) or trending ( P < 0.1) improvement over placebo in mean change from baseline at week 12/day 85 in several sign endpoints, including fluorescein staining in inferior, superior, corneal sum, and total sum regions; Lissamine Green staining in temporal, nasal, conjunctival sum, and total sum regions; and tear film breakup time.

also in 4,806 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.